AstraZeneca(US:AZN) Feng Huang Wang Cai Jing·2025-09-11 08:08Group 1 - The 2025 Global Service Trade Entrepreneurs Summit was successfully held on September 11, attracting over 500 high-level representatives from government departments, embassies, international organizations, and leading enterprises [1] - This summit is the fourth since the establishment of the Global Service Trade Alliance in 2022, indicating the growing importance of service trade on a global scale [1] Group 2 - AstraZeneca's Vice President of Global R&D in China, Chen Meng, highlighted the integration of AI across the entire drug development process, from discovery to clinical trials and commercialization [3] - Drug development typically takes 10-15 years and requires an investment of around $1 billion, with less than 10% of drug molecules entering clinical trials eventually receiving approval [3] - AstraZeneca aims to embed AI into every stage of the R&D process to enhance decision-making quality [3] Group 3 - The first main line involves integrating wet and dry laboratories, allowing experimental results to directly inform model outputs, creating a feedback loop for trial design [4] - The second main line focuses on optimizing drugs through multi-omics and multi-modal data to identify patient responders and expand indications using disease models and quantitative pharmacology [4] - The third main line aims to revolutionize clinical trials by using algorithms for patient recruitment, computer vision for quality control, and digital biomarkers for objective endpoint assessment [4] Group 4 - The convergence of these main lines is expected to transform traditional drug development methods, positioning China as a potential leader in AI-ready R&D paradigms [5]